Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Common Equity: 2020-2025

Historic Common Equity for Cellebrite DI (CLBT) over the last 3 years, with Sep 2025 value amounting to $447.7 million.

  • Cellebrite DI's Common Equity rose 50.07% to $447.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.7 million, marking a year-over-year increase of 50.07%. This contributed to the annual value of $336.0 million for FY2024, which is 882.17% up from last year.
  • Cellebrite DI's Common Equity amounted to $447.7 million in Q3 2025, which was up 9.62% from $408.4 million recorded in Q2 2025.
  • Cellebrite DI's Common Equity's 5-year high stood at $447.7 million during Q3 2025, with a 5-year trough of -$73.3 million in Q4 2021.
  • For the 3-year period, Cellebrite DI's Common Equity averaged around $174.2 million, with its median value being $39.4 million (2023).
  • As far as peak fluctuations go, Cellebrite DI's Common Equity slumped by 328.75% in 2024, and later spiked by 1,461.09% in 2025.
  • Cellebrite DI's Common Equity (Quarterly) stood at -$73.3 million in 2021, then soared by 200.71% to $73.9 million in 2022, then tumbled by 53.68% to $34.2 million in 2023, then soared by 882.17% to $336.0 million in 2024, then surged by 50.07% to $447.7 million in 2025.
  • Its Common Equity stands at $447.7 million for Q3 2025, versus $408.4 million for Q2 2025 and $363.5 million for Q1 2025.